Denali Therapeutics :
DNLI
DNLI
Stock Data
$18.30
$0.42 (2.24%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Denali Therapeutics Inc. is a pioneering biopharmaceutical firm focused on defeating neurodegenerative and lysosomal storage diseases. With a unique approach that involves engineering treatments to cross the blood-brain barrier, Denali is advancing a diverse portfolio. This includes therapies for conditions like Parkinson's disease, amyotrophic lateral sclerosis, and various forms of mucopolysaccharidosis. Collaborating with industry giants like Biogen and Takeda, Denali is at the forefront of developing innovative solutions for complex brain disorders. Founded in 2013, the company is based in South San Francisco, California.
All Denali Therapeutics Articles
6 Articles